Long-term disease-free survival following surgery and active specific immunotherapy with allogeneic vaccine in a patient with high-risk malignant melanoma of the vulva.
Vulvar malignant melanoma with deep vertical penetration of the tumor and involvement of regional lymph nodes carries a very poor prognosis. The case of a 25-year-old woman with a history of a Breslow depth 6.0 mm and Clark Level IV primary vulvar malignant melanoma, involving the anterior part of the left labium major, 1 cm from the clitoris, is reported. The patient had undergone a left radical hemivulvectomy and bilateral groin dissection. There were two of thirteen superficial left groin nodes containing metastatic melanoma. The patient had been treated postoperatively with an allogeneic specific anti-melanoma vaccine in combination with high-dose cimetidine and has survived without disease for more than five years. To the best of our knowledge this is the first case report in the literature of active specific immunotherapy with allogeneic vaccine in vulvar malignant melanoma. This case illustrates that the behavior of malignant melanoma, including vulvar malignant melanoma, is unpredictable and active specific immunotherapy with allogeneic vaccine may have a role in the postoperative treatment of high risk vulvar malignant melanoma.
Piura
B
B
Department of Obstetrics and Gynecology, Soroka Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel. piura@bgumail.bgu.ac.il
Meirovitz
M
M
Kedar
I
I
D000328:Adult; D019496:Cancer Vaccines; D002927:Cimetidine / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage; D006635:Histamine H2 Antagonists; D006801:Humans; D016233:Immunotherapy, Active; D008207:Lymphatic Metastasis; D008545:Melanoma / Q000276:immunology / Q000601:surgery / Q000628:therapy*; D011247:Pregnancy; D016896:Treatment Outcome; D014846:Vulvar Neoplasms / Q000601:surgery / Q000628:therapy*
D019496:Cancer Vaccines; D006635:Histamine H2 Antagonists; D002927:Cimetidine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor